SMALL LYMPHOCYTIC LYMPHOMA

This early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…

This study tests a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The trial includ…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tests a new drug, LOXO-305, against two standard treatment combinations for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with a BTK inhibitor. About 238 participants will be randomly assigned t…

This study tests a combination of two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The treatment length is guided by a sensitive blood test that looks for leftover cancer cells (minimal resi…

This study tests whether the drug lenalidomide, combined with a vaccine, can help the immune system fight early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people with high-risk genetic features. Lenalidomide works by cutting off blood supply t…

This study tested a combination of two drugs, ibrutinib and fludarabine, in 29 people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants took ibrutinib daily and received fludarabine for a short time. The goal was to see how many p…

This study tested whether a combination of ibrutinib (a targeted pill) plus rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 529 people took part. The main goa…

This study tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then te…

This study tests whether adding a newer drug (venetoclax) to the usual two-drug treatment (ibrutinib + obinutuzumab) helps older adults with untreated chronic lymphocytic leukemia (CLL) stay cancer-free longer. About 465 people aged 65+ will be randomly assigned to receive either…

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combo can kill more cancer cells than either drug alone. About 26 adults wil…

This study compares a new oral targeted therapy, nemtabrutinib, against standard chemoimmunotherapy in 300 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a specific genetic change (TP53 mutation). The main g…

This study tests if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds well, instead of continuing treatment indefinitely. The goal is to reduce side effects and preve…

This study tests whether adding a new targeted drug, pirtobrutinib, to the standard combination of venetoclax and rituximab helps people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. About 600 adults wh…

This study tested a combination of two targeted drugs, venetoclax and ibrutinib, in 234 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal was to see how well the drugs control the cancer, especially in patients whose disease came back or had h…

This phase 3 trial tests whether adding venetoclax to the standard combination of ibrutinib and obinutuzumab helps younger patients with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer worsening. About 720 participants will receive either the two-dru…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The treatment uses a patien…

This study tests an experimental antibody called epcoritamab, given alone or with other drugs, in people with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or not responded to treatment. About 195 adults will receive the drug under the skin or by mou…

This study tests a two-drug combination (ixazomib and rituximab) in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. The main goals are to check safety, find the right dose, a…

This study looks at whether giving vitamin D to cancer patients who are low in it can help them live longer without their disease getting worse. About 565 adults with certain lymphomas or leukemia will either get vitamin D or no extra vitamin D. The goal is to see if vitamin D re…

This phase 3 study tests whether zanubrutinib, a targeted oral drug, works better than the standard combination of bendamustine and rituximab for people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 590 participants who cannot receive…

This study tests a combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab as a first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific gene mutation (mutated IGHV) and no deletion in chromosome 17. The goal is to see if this drug …

This study tests whether people with chronic lymphocytic leukemia (CLL) can safely start venetoclax faster than the usual 5-week schedule. About 40 patients with new or returning CLL will take venetoclax daily with a quicker dose increase. The goal is to see if this faster approa…

This study tests whether a daily pill called pirtobrutinib works better than the standard chemo-immunotherapy combination (bendamustine + rituximab) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet been treated. About 309 participants wi…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…

This study tests an experimental drug called BGB-11417 in 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. The goal is to see if the drug can shrink or eliminate cancer cells. Particip…

This study tests a new drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal is to see if the drug is safe and can shrink or control the cancer. Participants take the drug by mouth, and the study tracks side effects and ho…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…